Hydrotalcite (Talcid) for relief of rebound acid symptoms after stopping long-term PPI therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational program collects real-world data from adults in Germany who discontinued long-term proton pump inhibitor therapy and now experience rebound acid symptoms. Participants will use hydrotalcite (Talcid) on demand while investigators record symptom relief, user experience, and acceptance. The approach relies on routine use rather than experimental dosing, with information gathered through patient reports and site follow-up. The aim is to describe how well hydrotalcite manages post-PPI dyspeptic complaints in everyday clinical practice.

Why it matters

Who can join: the full rules

Eligibility Criteria:

Adult female or male subjects aged ≥ 18

* Subjects who have discontinued daily PPI therapy (≥ 8 weeks of therapy) for which there is no current indication according to guidelines and approval status, e.g.

  * irritable bowel syndrome
  * subjects who receive Non-Steroidal Anti-Inflammatory drug (NSAID) treatment with no warning signals\* regarding ulcers
  * polymedication\*\* with no warning signals\* or side effects regarding ulcers
  * unclarified upper abdominal discomfort
  * mild forms of GERD; like Non-Erosive Reflux Disease (NERD), Los Angeles (LA) grade A/B esophagitis
* Suffer from acid-rebound due to a discontinuation of a non/no longer indicated long-term PPI therapy (≥ 8 weeks of therapy)
* No endoscopically diagnosed GERD\*\*\*
* No indication for a PPI-therapy according to guidelines.

Examples for guideline recommendations for a PPI-therapy:

* moderate - severe forms of reflux esophagitis
* gastric ulcer, duodenal ulcer
* Helicobacter pylori eradication
* moderate/severe forms of GERD - Los Angeles (LA) grade C/D esophagitis
* Zollinger-Ellison-Syndrome

No Talcid® contraindications or warnings as:

* pregnancy and lactation
* severe renal impairment
* hypophosphatemia
* existing myasthenia gravis
* impaired renal function
* Alzheimer's disease or other forms of dementia
* patients under low-phosphate diet
* hypersensitivity to the ingredients of Talcid®

  * Subjects who voluntarily agree to use Talcid® Chewable Tablets for relief of acid-related symptoms due to acid-rebound
  * Decision to initiate on-demand treatment of acid-related symptoms due to acid-rebound with Talcid® was made as per investigator's routine recommendation practice and by the subject
  * Subject purchases Talcid® for her/his own use
  * Signed informed consent
  * No participation in an investigational program with interventions outside of routine clinical practice
  * No contraindications according to the local marketing authorization

    \* Warning signals:
  * Age \> 60 (with one additional warning signal)
  * Previous history or family history of ulcers
  * Helicobacter pylori positive status \*\* Polymedication: defined as at least five medicinal products at the same time for a continuous therapy \*\*\* Endoscopy: LA grade C/ D esophagitis, Barrett esophagus, peptic stricture; pH- Impedance measurement: acid exposure \> 6%

Exclusion Criteria: not applicable

Where it's running

• Many Locations
  Multiple Locations, Germany Recruiting

Study contacts

• Study coordinator: Bayer Clinical Trials Contact
• Email: clinical-trials-contact@bayer.com
• Phone: 001888842

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• POEM vs Heller myotomy with Dor fundoplication for achalasia

  This trial tests POEM against laparoscopic Heller myotomy with Dor fundoplication to see which procedure better helps adults with achalasia.

  Recruiting Minia University · Minya, Minya Governorate · NCT07814027

• Detecting Barrett's Esophagus in Patients Without GERD Symptoms

  This study is testing a new way to find Barrett's esophagus in people who don’t have GERD symptoms by using a simple capsule test instead of the usual endoscopy.

  Recruiting at 5 sites Case Comprehensive Cancer Center · Aurora, Colorado and 4 other locations · NCT06687603

• Transpyloric versus gastric feeding for premature infants with bronchopulmonary dysplasia

  This trial will see if feeding premature infants with bronchopulmonary dysplasia directly into the small intestine (transpyloric) versus into the stomach reduces reflux and episodes of low oxygen.

  Recruiting at 3 sites Children's Hospital of Philadelphia · Palo Alto, California and 3 other locations · NCT06534359

• Measuring mucosal impedance to diagnose gastroesophageal reflux disease

  This study is testing a new way to measure the lining of the esophagus to see if it can help diagnose gastroesophageal reflux disease (GERD) better in patients who haven't improved with standard medications.

  Recruiting Hospital de Clinicas José de San Martín · Buenos Aires · NCT06339801

• Cow's-milk-protein-free diet versus omeprazole for reflux in infants

  This test compares a cow's-milk-protein-free diet to the medicine omeprazole for infants under one year who have troublesome gastroesophageal reflux.

  Recruiting Phase 4 Odense University Hospital · Aabenraa, Region Syddanmark and 2 other locations · NCT06255886

• Understanding gastrointestinal disorders in at-risk infants

  This study looks at how common gut problems are in at-risk infants, like those born early or who had trouble at birth, to see how these issues affect their growth and health in the first two years of life.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma · NCT06031025

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.